Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor Study Indication Phase NCT04154787 (CLNP023D12201) Idiopathic membranous nephropathy (iMN) Phase 2 NCT04578834 APPLAUSE-IgAN (CLNP023A2301) IgA nephropathy Phase 3 Patients 72 450 Primary Outcome Measures Change from baseline of UPCR derived from 24hr urine collections at Baseline and Week 24 Arms Intervention Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine collection) at 9 months Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated over 24 months Arm 1 - LNP023 200mg BID Arm 2 - Placebo BID LNP023 low dose LNP023 high dose Rituximab Patients with biopsy proven iMN who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria Primary IgA Nephropathy patients Target Patients Read-out Milesstone(s) 2023 Publication TBD 68 Investor Relations | Q3 2021 Results 2023 Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: Study Design Wong et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY NOVARTIS | Reimagining Medicine

View entire presentation